Olivia Vizier

empowered

Platform for Meaningful Delivery of Cancer Vaccines for Multiple Tumor Types with Andrew Hall IMV

Andrew Hall is the CEO of IMV Inc, which has developed a platform based on a lipid-in-oil technology that encapsulates the therapeutic. When injected subcutaneously, the drug remains in a specific location to reinvigorate the immune system to overcome the tumor surveillance that allows cancer to grow.

Platform for Meaningful Delivery of Cancer Vaccines for Multiple Tumor Types with Andrew Hall IMV Read More »

endpoints

Bristol Myers vets tie up another all-stock deal, lining up clinical-stage oncology pipeline

Portage Biotech is helmed by CEO Ian Walters and CSO Robert Kramer, and backed by three biotech entrepreneurs — UK investor Jim Mellon, ex-Biohaven board member Declan Doogan and early Medivation backer Greg Bailey — who have whipped up a whole slate of different ventures aimed at drug development.

Bristol Myers vets tie up another all-stock deal, lining up clinical-stage oncology pipeline Read More »

pharma shots

PharmaShots Interview: Mahesh Karande, CEO of Omega Therapeutics Shares Insights from the Preclinical Data Presented at the AACR 2022

OTX-2002 is our lead Omega Epigenomic Controller™ (OEC) candidate designed to downregulate the expression of c-Myc (MYC), a key gene involved in cellular growth commonly overexpressed in cancer cells. OECs are programmable mRNA medicines that encode a two-part protein: a DNA binding domain that specifies the target location on the DNA, which we call EpiZips™,

PharmaShots Interview: Mahesh Karande, CEO of Omega Therapeutics Shares Insights from the Preclinical Data Presented at the AACR 2022 Read More »

empowered

Using Antibodies from Memory B Cells to Restore Immune Response to Autoimmune Oncologic and Infectious Diseases with Matthew Robinson Immunome

Matthew explains, “At Immunome, we believe that the antibodies that these B cells are making have an ability to see the different types of tumor antigens, or the specific epitopes on infectious disease. Our platform allows us to see that disease through the lens of the human B cell. We can interrogate what those antibodies

Using Antibodies from Memory B Cells to Restore Immune Response to Autoimmune Oncologic and Infectious Diseases with Matthew Robinson Immunome Read More »

empowered

Identifying Targets on Problematic T Cells to Treat Immunological Diseases with Dr. Judy Chou AltruBio

Dr. Judy Chou is the President and CEO of AltruBio which is developing novel immunomodulators to treat immunological diseases such as autoimmune and inflammatory diseases. Their first-in-class agnostic antibody has a unique mechanism to regulate T cell homeostasis. Currently, there is a clinical trial for SR-aGVHD, steroid-refractory acute graft-host disease and an investigation is underway

Identifying Targets on Problematic T Cells to Treat Immunological Diseases with Dr. Judy Chou AltruBio Read More »

endpoints

LOW-PROFILE BIOTECH LED BY BRISTOL MYERS VETS GRABS A SUITE OF ADENOSINE RECEPTOR ANTAGONISTS VIA TINY BUYOUT

Portage Biotech — which is led by two Bristol Myers Squibb vets, CEO Ian Walters and CSO Robert Kramer — is buying out New York’s Tarus Therapeutics in a $21 million all-stock deal that gives it $3 million worth of liabilities on top of four adenosine receptor antagonists, two of which are already in Phase

LOW-PROFILE BIOTECH LED BY BRISTOL MYERS VETS GRABS A SUITE OF ADENOSINE RECEPTOR ANTAGONISTS VIA TINY BUYOUT Read More »

A Network And Pivot Model For Success In Cancer Drug Development

When CEO Avanish Vellanki founded and incorporated Rain Therapeutics on his living room couch in the spring of 2017, there was no drug in development, no money, and a team of only four people. Five years later, after halting the development of its first licensed product, the Newark, CA-based precision oncology company awaits topline results

A Network And Pivot Model For Success In Cancer Drug Development Read More »

opthalmology times

MEIRAGTX ANNOUNCES DATA FROM PHASE 1/2 CLINICAL STUDY OF GENE THERAPY FOR PATIENTS WITH X-LINKED RETINITIS PIGMENTOSA

MeiraGTx today announced top-line data from the Phase 1/2 clinical study MGT009 (NCT03252847) of botaretigene sparoparvovec (formerly referred to as AAV-RPGR), an investigational gene therapy in development for the treatment of patients with X-linked retinitis pigmentosa (XLRP) with disease-causing variants in the RPGR gene.

MEIRAGTX ANNOUNCES DATA FROM PHASE 1/2 CLINICAL STUDY OF GENE THERAPY FOR PATIENTS WITH X-LINKED RETINITIS PIGMENTOSA Read More »

biospace

RAIN TARGETS NORMAL P53 EXPRESSION WITH POSSIBLE PAN-CANCER THERAPEUTIC

Rather than target mutated p53, Rain Therapeutics is looking at normal p53 expression as part of its novel mouse double minute 2 homolog (MDM2) inhibitor therapy. In the coming 12 months, Rain expects to have an interim readout for a Phase II study of its liposarcoma therapy, called milademetan (Rain-32), and a pivotal readout for its Phase III trial

RAIN TARGETS NORMAL P53 EXPRESSION WITH POSSIBLE PAN-CANCER THERAPEUTIC Read More »

empowered

Developing DNA Gene Therapies to Treat Chronic Inflammatory Diseases with Dr. Diem Nguyen Xalud Therapeutics

Dr. Diem Nguyen is the CEO of Xalud Therapeutics, a DNA delivery gene therapy company striving to develop and deliver medicines for large, broad-based disease indications like chronic inflammatory diseases, particularly musculoskeletal diseases like osteoarthritis of the knee and as well as neurodegenerative diseases like MS and ALS. Earlier in her career, Diem was the global

Developing DNA Gene Therapies to Treat Chronic Inflammatory Diseases with Dr. Diem Nguyen Xalud Therapeutics Read More »

diabetes-connections

“This is Becoming a Reality” – Sernova’s Cell Therapy Approach to a Functional T1D Cure

Big news from Sernova, one of the companies hoping that implantable stem cells will be a functional cure for diabetes. They recently announced that the first person in their trials with type 1 is completely off injected or infused insulin – and is making their own.

“This is Becoming a Reality” – Sernova’s Cell Therapy Approach to a Functional T1D Cure Read More »

real-world effectvieness of g-csf In pts with bc

Douglas W. Blayney, MD, FASCO, Clinical researcher and breast oncologist, Professor of Medicine at Stanford University. In this video, he speaks about the ASCO 2022 Abstract – Real-world effectiveness of prophylactic granulocyte colony-stimulating factor (G-CSF) early (week 1) and late (weeks 2-3) in the cycle for the prevention of febrile neutropenia (FN) among patients (pts)

real-world effectvieness of g-csf In pts with bc Read More »

pharma shots

PharmaShots Interview: In Conversation with Portage’s CEO and Director, Dr. Ian Walters, Where he Shares Insights on Ongoing Clinical-Stage and Development Programs

We are pleased with the progress made so far in our iNKT agonist programs and look forward to exploring these treatments further in future clinical trials. One recent collaboration that we announced was with Stanford University to explore the use of iNKT agonists with iNKT cell therapy.  

PharmaShots Interview: In Conversation with Portage’s CEO and Director, Dr. Ian Walters, Where he Shares Insights on Ongoing Clinical-Stage and Development Programs Read More »

biospace

Sernova Cell Pouch Keeps T1 Diabetes Patient Insulin Free for 2 Years

Sernova’s Cell Pouch is an implantable device that releases the primary donor islets. The device is implanted under the skin in a minimally-invasive procedure. At this time, Toleikis noted they are unsure of how long the device will continue to function and release the islets, which he said can read blood sugar levels and produce

Sernova Cell Pouch Keeps T1 Diabetes Patient Insulin Free for 2 Years Read More »